ICPT
62.34 +4.62 (8.00%)
Otra que tiene un bonito gap por tapar en los 100 usd y tanto en diario como en semanal tiene un MACD haciendo un Golden Cross , lleva dos soldados blancos despues de hacer doble suelo y dejarnos la figura de bebe abandonado.ademas de romper la bajista que desde Octubre llevaba mas un Chaiking Money Flow hablando de presion de compra,
En 2014 llego a valer 460 usd/accion
Market Cap 1.44B Inst Own 75.60% Target Price 121.15
Amgen's Aimovig successful in late-stage study in treatment-resistant migraine
Amgen (NASDAQ: AMGN) announces successful results from a Phase 3b clinical trial, LIBERTY, evaluating Aimovig (erenumab) in patients with episodic migraine who have failed two to four prior treatments.
The study met the primary endpoint demonstrating a statistically significantly greater proportion of patients experiencing at least a 50% reduction from baseline in monthly migraine days compared to placebo. All secondary endpoints were also met.
No new safety signals were reported.
Complete data will be submitted for presentation at an upcoming scientific conference.
The company's U.S. marketing application is currently under FDA review with an action date of May 17. Novartis will co-commercialize.
Acerca del management de varias bios, comentario de biotech2k que comparto plenamente:
There are a few companies who have great science but weak managements. I just can't get behind a weak management. Very few of them ever fix their problems without a management change. I have a list of bad actors. Some are worse then others, but all have had management miss steps.
They are PTLA, BLCM, OMER, TGTX, are of the least offenders. These are the ones where the management still has some redeemable qualities. Then there are the ones I would not touch with a 10' pole like XON and ZIOP. GILD and CELG are somewhere in the middle.
La nueva realidad del sector?
MENSUAL
XBI
Nuevos maximos historicos
IBB
rezagada, lastrada por REGN, CELG y GILD?
Qué le pasa a XON que no levanta cabeza? A mí me estuvo tentando en los 11bajos, ya la saqué a comentar aquí en ese momento.
ACAD
TGTX
ACHN
KERX
Slow but steady.
En cuanto supere los 5,12 se ira a testar el inicio del gap
Estoy de acuerdo en el discurso pero no en los ejemplos. No pondría de ejemplo de buen manager a Weis (TGTX) ni me parece el peor Kirk (XON,ZIOP)
